NASDAQ: RLYBRallybio Corp Stock
$0.51+0.17 (+50%)
Updated Jul 8, 2025
Rallybio shares are trading higher... find out Why RLYB Price Moved with a free WallStreetZen account
Why Price MovedRLYB Price
$0.51
Fair Value Price
$0.60
Market Cap
$21.26M
52 Week Low
$0.22
52 Week High
$1.54
P/E
-0.47x
P/B
0.39x
P/S
34.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$848.00k
Earnings
-$48.19M
Gross Margin
100%
Operating Margin
-5,682.19%
Profit Margin
-5,682.2%
Debt to Equity
0.07
Operating Cash Flow
-$44M
Beta
1.18
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RLYB Overview
Rallybio Corporation is a clinical-stage biotechnology company offering programs for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company is also focused on developing therapies that address diseases of complement dysregulation, including Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, and ophthalmic disorders. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RLYB's potential to beat the market
- RLYB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RLYB
RankedUnranked of 475
RankedUnranked of 475
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.59 | A | |
| $7.59 | A | |
| $43.51 | A |
Be the first to know about important RLYB news, forecast changes, insider trades & much more!
RLYB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RLYB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RLYB ($0.51) is undervalued by 14.37% relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RLYB ($0.51) is not significantly undervalued (14.37%) relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLYB due diligence checks available for Premium users.
Valuation
RLYB fair value
Fair Value of RLYB stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$0.60
Undervalued by
14.53%
RLYB ($0.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLYB ($0.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RLYB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
-136.92x
Market
30.75x
RLYB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
4.53x
RLYB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RLYB's financial health
Profit margin
Revenue
$212.0k
Net Income
-$9.4M
Profit Margin
-4,452.4%
RLYB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RLYB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$58.0M
Liabilities
$3.9M
Debt to equity
0.07
RLYB's short-term assets ($57.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLYB's short-term assets ($57.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLYB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
$11.1M
Financing
$0.0
RLYB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RLYB vs Biotech Stocks
Rallybio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.